Images List Premium Download Classic

Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Uses of mito-ob transgenic mice
University Of Manitoba
March 30, 2017 - N°20170089888

The mito-ob obese mouse model overexpresses the mitochondrial protein prohibitin (phb). Mito-ob male mice develop insulin resistance in addition to obesity and they do not develop overt diabetes. It has been discovered that these mice also spontaneously develop nonalcoholic steatohepatitis (nash) and hepatocarcinogenesis over time. Also described is a mutant mito-ob mouse that develops lymphadenopathy and histiocytosis.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Glucagon and glp-1 co-agonist compounds
Eli Lilly And Company
December 22, 2016 - N°20160368960

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Differential diagnosis of liver disease
The Regents Of The University Of California
October 20, 2016 - N°20160305925

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls. Specifically, the invention relates to ...
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
Intekrin Therapeutics, Inc.
September 15, 2016 - N°20160263098

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (nafld) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective pparγ agonist, int131 and optionally vitamin e or compositions thereof. Naflds that may be treated with methods and compositions of the present invention ...
Engineered polypeptides having enhanced duration of action and reduced immunogenicity
Intekrin Therapeutics, Inc.
July 21, 2016 - N°20160207974

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Chi3l1 for the detection and treatment of nonalcoholic steatohepatitis
Yale University
May 19, 2016 - N°20160139149

Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (nash) measuring chi3l1 levels. In some embodiments, the methods described herein can distinguish nash from nonalcoholic fatty liver disease. Chi3l1 levels can also be used to monitor treatment progress in patients having nash. Also disclosed herein are compositions and methods for treating nash by targeting chi3l1.
Engineered polypeptides having enhanced duration of action
Aegerion Pharmaceuticals, Inc.
May 19, 2016 - N°20160137709

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Highly soluble leptins
Aegerion Pharmaceuticals, Inc.
March 24, 2016 - N°20160083446

The disclosure provides chimeric polypeptides and nucleic acid molecules encoding chimeric polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type i and type ii). Additional diseases and disorders which can be treated by the compounds and ...
Method of treating advanced non-alcoholic steatohepatitis
Aegerion Pharmaceuticals, Inc.
November 12, 2015 - N°20150322004

Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for inhibiting or treating advanced nonalcoholic steatohepatitis, conditions leading to or arising from it, and/or negative effects of each thereof.
Novel biomarkers for non-alcoholic fatty liver disease, and methods for detecting non-alcoholic fatty liver disease ...
Mcbi, Inc.
August 06, 2015 - N°20150219672

The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to ...
Anti-angptl3 antibodies and uses thereof
Regeneron Pharmaceuticals, Inc.
July 16, 2015 - N°20150197564

A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hangptl3) is provided. The human anti-hangptl3 antibodies are useful in treating diseases or disorders associated with angptl3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hangptl3 ...
Methods for the treatment of nonalcoholic steatohepatitis
Universite Paris Descartes
February 26, 2015 - N°20150057332

The present invention relates to the treatment of nonalcoholic steatohepatitis (nash), in particular to a compound that inhibits mir-21 expression for use in the treatment of nonalcoholic steatohepatitis.
Nonalcoholic Steatohepatitis Patent Pack
Download + patent application PDFs
Nonalcoholic Steatohepatitis Patent Applications
Download + Nonalcoholic Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Nonalcoholic Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compounds for control of appetite
Universite Paris Descartes
September 18, 2014 - N°20140274887

This invention relates generally to neuropeptide y (“npy”) y4 receptor agonists including pancreatic polypeptide (pp), analogs thereof, and peptide fragments of pp, e. G. Pp(32-36), and analogs thereof, to pharmaceutical compositions containing such y4 receptor agonists, and to methods for treatment of mammals using the same. The npy y4 receptor agonists may be administered to ...
Engineered poypeptides having enhanced duration of action and reduced immunogenicity
Universite Paris Descartes
September 11, 2014 - N°20140256621

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, ...
Lysosomal acid lipase therapy for nafld and related diseases
Universite Paris Descartes
August 21, 2014 - N°20140234288

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
Universite Paris Descartes
July 03, 2014 - N°20140187633

In various embodiments, the present invention provides methods of treating and/or preventing nash and/or pbc comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Loading